Cybin (CYBN)'s international patent filing this morning will establish this NYSE listed company as the leader at solving America's crisis of COVID-19 induced anxiety through the inhalation of psychedelic drugs.
CYBN has a discovery pipeline of 50+ different proprietary psychedelic molecules based upon DMT, MDMA, Psilocybin, and other psychedelics.
CYBN currently has 4 active drug programs targeting Major Depressive Disorder (CYB001), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Therapy Resistant Psychiatric Disorders (CYB005).
CYBN has received Phase II clinical trial approval for CYB001 targeting Major Depressive Disorder.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from CYBN of USD$100,000 cash for a one-year marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.